Login to Your Account

Other News To Note

Wednesday, September 25, 2013
• Ipsen SA, of Paris, reported positive top-line findings from the primary endpoint of the ELECT study assessing the effect of Somatuline Autogel/Somatuline Depot (lanreotide) Injection 120 mg in controlling symptoms in patients with neuroendocrine tumors associated with carcinoid syndrome.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription